Dechra
Libromide 325 mg for dogs 500 tablets

Helps in the control of refractory cases of epilepsy in dogs

Prescription required* (Exceptions apply)

Libromide 325 mg is a plain white circular biconvex 9.5 mm tablet with a single scored line on one face. This product is an anti-epileptic agent for use as an adjunct to phenobarbital in the control of refractory cases of epilepsy in dogs.

One Libromide 325 mg tablet contains:

Active substance:

  • Potassium bromide 325 mg

Excipients:

  • Lactose monohydrate
  • Microcrystalline cellulose
  • Magnesium stearate
  • Stearic acid
  • Saccharin sodium

Libromide 325 mg:

  • Must no be used in cases of known hypersensitivity to bromide, or to any of the excipients.
  • Must no be used in cases in dogs with severe renal insufficiency.

Libromide 325 mg posology:

  • For oral use. Administer with food.
  • Administer to dogs with refractory epilepsy, where seizure control is unsatisfactory despite appropriate phenobarbital therapy, when serum phenobarbital concentrations are at a steady-state within the therapeutic range.
  • The dose should be titrated to the individual dog as the required dosage will depend on the nature and severity of the underlying disease.
  • Administer with food at an initial dose of 15 mg/kg bodyweight twice daily(equivalent to a total daily dose of 30 mg/kg). Twice daily administration is advised in order to reduce the risk of gastrointestinal disturbances.
  • Due to the 24 day half-life of bromide, it can take several weeks or months to achieve steady-state serum concentrations. For at least the first three months following commencement of therapy, measure serum bromide concentrations every 4 weeks. The expected therapeutic serum bromide concentration (when used in conjunction with phenobarbital) is 800 to 2000 μg/ml. Adjustments to the dose should be made with regard to the frequency of seizures, the half-life of bromide and the serum bromide concentration. Long term monitoring of serum bromide (and associated phenobarbital) concentrations should be performed as clinically justified by the individual case.
  • Close monitoring for side effects is advisable at higher serum bromide concentrations.
  • Use in dogs with a body weight of less than 11 kg should be subject to a risk/benefit assessment, see section 4.5 of the pdf.

Libromide 325 mg is a plain white circular biconvex 9.5 mm tablet with a single scored line on one face. This product is an anti-epileptic agent for use as an adjunct to phenobarbital in the control of refractory cases of epilepsy in dogs.

One Libromide 325 mg tablet contains:

Active substance:

  • Potassium bromide 325 mg

Excipients:

  • Lactose monohydrate
  • Microcrystalline cellulose
  • Magnesium stearate
  • Stearic acid
  • Saccharin sodium

Libromide 325 mg:

  • Must no be used in cases of known hypersensitivity to bromide, or to any of the excipients.
  • Must no be used in cases in dogs with severe renal insufficiency.

Libromide 325 mg posology:

  • For oral use. Administer with food.
  • Administer to dogs with refractory epilepsy, where seizure control is unsatisfactory despite appropriate phenobarbital therapy, when serum phenobarbital concentrations are at a steady-state within the therapeutic range.
  • The dose should be titrated to the individual dog as the required dosage will depend on the nature and severity of the underlying disease.
  • Administer with food at an initial dose of 15 mg/kg bodyweight twice daily(equivalent to a total daily dose of 30 mg/kg). Twice daily administration is advised in order to reduce the risk of gastrointestinal disturbances.
  • Due to the 24 day half-life of bromide, it can take several weeks or months to achieve steady-state serum concentrations. For at least the first three months following commencement of therapy, measure serum bromide concentrations every 4 weeks. The expected therapeutic serum bromide concentration (when used in conjunction with phenobarbital) is 800 to 2000 μg/ml. Adjustments to the dose should be made with regard to the frequency of seizures, the half-life of bromide and the serum bromide concentration. Long term monitoring of serum bromide (and associated phenobarbital) concentrations should be performed as clinically justified by the individual case.
  • Close monitoring for side effects is advisable at higher serum bromide concentrations.
  • Use in dogs with a body weight of less than 11 kg should be subject to a risk/benefit assessment, see section 4.5 of the pdf.
124.60
Order within 0h 46m 24s (before 12AM)
And receive your order
on Tuesday 7 July
AIR FREIGHT

Customers who buy this product, usually buy: